Navigation Links
TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
Date:9/17/2009

DOYLESTOWN, Pa., Sept. 17 /PRNewswire/ -- Following the recent CE Mark certification of the vProtect(TM) Luminal Shield, the novel self-expanding coronary stent system will be the focus of scientific presentations and roundtable discussions on lesion-specific therapy for coronary artery disease at TCT 2009, September 21-25, San Francisco, CA. The vPredict(TM) Optical Catheter System, a diagnostic device, also from Prescient Medical, will be featured in several presentations.

All sessions will be held at the Moscone Center. Media contacts welcome. Executives from Prescient Medical will be available to answer questions in advance or following sessions.

8:00 am-6:45 pm, Room 131, Monday, September 21st:

Both devices will be discussed in the day-long scientific symposium "Vulnerable Plaque: Emerging Direction for Diagnosis and Treatment." Professor Patrick W. Serruys of Erasmus Medical Center in Rotterdam will discuss clinical experience with the vProtect(TM) Luminal Shield in stabilizing vulnerable plaque at 5:05 pm. Prof Serruys commented, "Recent developments in the field of vulnerable plaque are very exciting." He added, "We are finally making progress in characterizing, understanding, and potentially treating these lesions." Other key presentations include discussions of preclinical and clinical studies by Juan Granada, MD, of the Cardiovascular Research Foundation, and Giuseppe Sangiorgi, MD, Director of Interventional Cardiology at the University of Rome at 9:00 am, 3:30 pm, and 4:45 pm.

4:00 pm-4:20 pm, Room 134, Wednesday, September 23rd:

Dr. Granada, will present key findings relating to the low-injury self-expanding design of the vProtect(TM) Luminal Shield during "Coronary Stent Design and Device Development."

4:45 pm-4:55 pm, Room 133, Thursday, September 24th:

Dr. Granada will present additional data on the vProtect(TM) Luminal Shield during "The Re-Emergence of Nitinol Self-Expanding Coronary Stents," a special session dedicated to exploring the re-emergence of self-expanding coronary stents led by the vProtect(TM) Luminal Shield. Dr. Granada commented, "It has become clear that stent designs and materials should be tailored to the pathophysiology of the lesion to be treated. The Shield is designed specifically to minimize arterial injury and its consequences, making it ideal for softer plaques."

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. The company is the recipient of the 2009 Frost and Sullivan Award for Product Innovation of the Year Award for vProtect(TM) Luminal Shield. For more information about Prescient Medical and its products, please visit www.prescientmedical.com


'/>"/>
SOURCE Prescient Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
2. 4th BTLtec Conference on 24-25 Sep in Graz, Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies, Syngas Application, BTL Value Chain and a Site Visit to the Biomass CHP Gussing Plant.
3. Magellan Diagnostic Businesses to Feature Automated Systems and Diagnostic Tests at Clinical Lab Expo
4. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
5. New Scientific Worldview Biocentrism Featured in The Huffington Post - #1 Weblog in the World
6. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
7. NeoStem Featured in Business Week; Promising Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article
8. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
9. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
10. ChemoCentryxs Traficet-EN(TM) Phase II/III Induction Phase Data in Crohns Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
11. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... and GREENWICH, Conn. ... private investment firm focused on venture growth investments ... promotion of Josh Richardson , M.D. to ... investments in biotechnology companies.  He is a board ... important roles in Longitude,s investments in Aimmune Therapeutics, ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
Breaking Biology Technology:
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
Breaking Biology News(10 mins):